Close Menu

This article has been updated from a previous version to include comments made by Qiagen executives during its earnings call.

NEW YORK (GenomeWeb) – Qiagen reported after the close of the market Monday that its third quarter revenues grew 7 percent year over year on both a reported basis and at constant exchange rates (CER).

For the three months ended Sept. 30, Qiagen reported revenues of $364.0 million, up from $338.7 million a year ago and just beating the average analyst estimate of $363.3 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.